FRANKLIN LAKES, N.J., Aug. 2, 2011 /PRNewswire/ — BD (Becton,
Dickinson and Company) (NYSE:
BDX), a leading global medical technology company, today
reported quarterly revenues of $2.014 billion for the third fiscal
quarter ended June 30, 2011, representing an increase of 10.0
percent from the prior-year period. On a foreign
currency-neutral basis, revenues increased 4.8 percent.
“We are pleased with our solid results this quarter, with
all three segments contributing to growth,” said Edward J.
Ludwig, Chairman and Chief Executive Officer. “Gross
margin expansion reflecting favorable product mix has offset some
of the headwinds we have been facing as a result of a challenging
macroeconomic environment and increased raw material
costs.”
Agreement to Acquire Carmel Pharma, ABOn July 27, 2011, the
Company announced that it had signed a definitive agreement to
acquire Carmel Pharma, AB, a Swedish company that manufactures the
PhaSeal® System. This is the leading closed-system drug
transfer device for the safe handling of hazardous drugs that are
packaged in vials. The acquisition is expected to close prior
to the end of this fiscal year.
Third Quarter and Nine-Month Fiscal 2011 Operating
ResultsReported diluted earnings per share from continuing
operations for the third quarter were $1.51, compared with $1.23 in
the prior-year period, representing a 22.8 percent increase, or
13.8 percent on a currency-neutral basis.
For the nine-month period ending June 30, 2011, reported
diluted earnings per share from continuing operations were $4.23,
compared with $3.66 in the prior-year period. The prior-year period
included a non-cash charge of $8.9 million, or $0.04 per share,
related to healthcare reform impacting Medicare Part D
reimbursements. Excluding that item, earnings per share from
continuing operations incr
‘/>”/>
SOURCE
